Blackhawk Growth Corp.
BLRZF
Other OTC0.02
USD
+0.01
- -
ISIN
CA09237D2068
CUSIP
09950M106
Return %
Stock
S&P500
1Y
168.33
20.98
3Y
-97.94
70.79
5Y
-99.77
73.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Justin Adam Hanka
- Full Time Employees
- 834
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 303-750 West Pender Street Vancouver BC Canada V6C 2T7
- IPO Date
- Mar 22, 2013
- Website
- blackhawkgrowth.com
- Similar Companies
- Business
- Blackhawk Growth Corp. (CSE:BLR; OTC:BLRZF) is a publicly listed investment issuer that acquires and invests in assets, technology and projects in the technology and life sciences sectors, including medical technologies, pharmaceuticals, digital health, software, big data and AI; it focuses on opportunities with global scalability and positive impact on health and human wellbeing, providing equity and short-term loan investments to fund research and development, product development, commercialization, sales and expansion activities. The company, formerly known as Blackhawk Resource Corp., was incorporated in 1986 and is headquartered in Vancouver, British Columbia, Canada, with operations centered in North America. Blackhawk Growth employs an investment model leveraging its status on the Canadian Securities Exchange to commercialize intellectual property and projects for potential public listings, mergers, acquisitions or divestments to create shareholder value. Its core investment activities target disruptive innovations in health and medical technologies, AI-driven solutions, machine learning and engineering projects with defendable intellectual property; the firm sources opportunities through relationships with research organizations, scientists and engineers, prioritizing companies with experienced management, clear business models and identifiable global distribution pathways. A notable past transaction involved acquiring and developing MindBio, a biopharma project focused on microdosing treatments for mental health conditions, which Blackhawk advanced through clinical trials, team building, capital raising and spin-out as a separate listed entity (CSE:MBIO) in recent years, distributing shares 1:1 to its shareholders. In August 2025, Blackhawk Growth provided an update on sourcing new project opportunities through partnerships, potential acquisitions and collaboration projects in the medical technology, health and wellness fields, signaling a strategic expansion in these areas. The company maintains ongoing development of several large-scale initiatives involving technology, big data analysis, AI and unique scientific innovations, while inviting accredited and institutional investors to co-participate in select deals alongside its own capital. It continues to pursue multiple spin-outs and listings annually, drawing on equity capital markets expertise in Australia and North America.
Blackhawk Growth Corp. Announces a Director Resignation, Effective July 3, 2026